Back to top

Analyst Blog

Recently, the US Food and Drug Administration (FDA) approved Baxter International Inc.’s (BAX - Analyst Report) Rixubis for routine prophylactic treatment of Hemophilia B. This came as a major boost for the company’s BioSciencebusiness.

Rixubis is the first recombinant factor IX (rFIX) to treat genetic disorder in 15 years and expands Baxter’s product line for hemophilia treatments. The FDA approval complements the company’s strategy to reduce bleeding disorders one patient at a time.

Hemophilia B or Christmas disease is a chronic disease resulting from the lack of generation of clotting factor IX, a naturally occurring protein in blood. The complications include bleeding episodes and hemophilic arthropathy (bleeding into a joint) leading to hospitalization. Rixubis was approved based on a pivotal Phase I/III study on 73 patients treated previously.

The market for Hemophilia B, the second most common type of hemophilia, is huge and rapidly growing. According to the latest data provided by World Federation of Hemophilia, more than 4,000 people in the U.S. and around 26,000 worldwide have been currently detected with Hemophilia B Thus, with Rixubis, the only FDA approved rFIX for routine prophylaxis and control of bleeding episodes, Baxter has a huge scope to capture this underpenetrated market.

Baxter is striving to expand its hemophilia business through the international expansion of its product line. The company is also trying to introduce recombinant therapy options for more hemophilia patients worldwide. In 2012, Baxter’s ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes with hemophilia A (congenital factor VIII deficiency) received regulatory approval in China.

In March, the company acquired the investigational hemophilia compound OBI-1 from Inspiration BioPharmaceuticals, Inc. and certain other OBI-1 related assets from Ipsen Pharma S.A.S. OBI-1 is a recombinant porcine factor VIII (rpFVIII) and is being investigated for treatment of bleeding in people with acquired hemophilia A and congenital hemophilia A patients with inhibitors.

Although we believe that the recent developments including a strong product line and several products in late stage clinical development are encouraging, we are concerned about relative stagnation in sales, a difficult outlook for hospital spending and tightening of reimbursement.

The stock currently carries a Zacks Rank #3 (Hold). However, Cryolife (CRY - Snapshot Report), Natus Medical (BABY - Snapshot Report) and Heartware International (HTWR - Snapshot Report), which carry a Zacks Rank #1 (Strong Buy), are expected to do well.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%